@RShouval

Precision Cellular Therapy | Attending - BMT and Cellular Therapy Service @sloan_kettering

 Manhattan, NY
mskcc.org/research-areas/research-teams/precision-cellular-therapy-laboratory
Joined December 2018
  • Tweets926
  • Following371
  • Followers1.5K
91Media
🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter nature.com/articles/s41591-0… 🧵Let’s break it down

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

Nature Medicine - A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T...

nature.com
3
39
2
148
14,069
Now online: CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All doi.org/10.1158/2643-3230.BC…
3
1
194
Had a wonderful time discussing #CART cure / resistance/ secondary malignancies with my friend @NicoGagelmann @MythsFactsPod
Nico Gagelmann
@NicoGagelmannOct 5
Excited to share the next episode of @MythsFactsPod! The myth of CAR-T, how it changed hematology and what challenges remain... beautifully outlined by @RShouval. Comment and give feedback🙏❤️ youtu.be/hQjMKei8vhM?is=5DWG…

‘CAR T cells CURE and CAUSE cancer’ w. Roni Shouval

In this episode, together with Roni Shouval, we discuss the evoluti...

youtube.com
3
12
704
Roni Shouval retweeted
Nico Gagelmann
@NicoGagelmannSep 27
What is the magic and danger of CAR-T cells. @MythsFactsPod will stream their 4th episode next week with @RShouval discussing what is cure and how real is the risk of second malignancies with this living drug. youtu.be/gBUZyRgAvaY?is=s9r3…

‘CAR T cells CURE and CAUSE cancer’ | TEASER w. Roni Shouval - available from OCTOBER 4!

FULL EPISODE available from October 4!We are happy to announce ou...

youtube.com
1
7
14
2,830
Roni Shouval retweeted
Jonas Schluter@jonasschluterSep 30
Our new paper in @Nature . Over 9K precisely recorded meals paired with longitudinal microbiome data reveals that dietary sugars consumed during antibiotic treatment exacerbate gut ecosystem damage. With @tsonipeled & @DrMvandenBrink labs. nature.com/articles/s41586-0…
6
11
1
25
2,934
Roni Shouval retweeted
Kai Rejeski@KRejeskiAug 25
Not all CHIP is created equal when it comes to CAR-T…TP53 mutant CHIP stands out: ➡️ more cytopenias, higher baseline CAR HEMATOTOX, reduced CAR expansion and inferior outcomes ➡️ distinct inflamm. proteomic signature Just out in 📄 in @LeukemiaJnl nature.com/articles/s41375-0…

TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR...

Leukemia - TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy

nature.com
1
14
35
3,257
Roni Shouval retweeted
Nico Gagelmann
@NicoGagelmannJul 12
Very excited to see the first episode out! PTCy - for ALL donors? Post-transplant cyclophosphamide revolutionized the field, offering new hope to patients worldwide. How did all this start, where are we now? Thanks to whole team of @MythsFactsPod youtu.be/3lAMYEFp8ek?is=9KFu…
3
13
1
45
11,042
Can early CAR T-cell redosing improve the therapeutic index of CAR T-cell therapy? Our study, now published in @Haematologica, suggests that an early (day +14) second CD19 CAR T-cell infusion may increase CAR T-cell exposure, prolong persistence, and improve response durability.
4
22
1
55
6,677
A new study by @RShouval and team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @MSKCancerCenter Learn more: bit.ly/4vYu0yL
A headshot of Bone Marrow Transplant Specialist & Cellular Therapist Roni Shouval, the lead author of this study.

ALT A headshot of Bone Marrow Transplant Specialist & Cellular Therapist Roni Shouval, the lead author of this study.

1
10
9
1,491
Excited to share our new publication in @JAMAOnc. In a meta-analysis of bispecific antibodies in lymphoma/myeloma, second primary malignancies were reported in 3.5% of patients. 20 studies | 26 cohorts | 2,551 patients jamanetwork.com/journals/jam… #lympoma #myeloma #BispecificAbs
2
6
23
1,202
Grateful to Jaromir Tomasik, Tobias Tix, @KRejeski , and all collaborators for this important work.
1
3
230
These estimates require context: follow-up was relatively short, outcome definitions were heterogeneous, and SPM reporting was inconsistent across studies. As bispecific antibodies move into earlier lines of therapy, standardized long-term safety surveillance will be essential.
2
99
Roni Shouval retweeted
Anil Palepu@apalepu13Jun 17
Thrilled to share that our paper on AMIE—our conversational medical AI—is now published in @Nature. We wanted to tackle one of the most challenging areas in clinical AI: management reasoning over multiple patient visits. nature.com/articles/s41586-0…
9
56
2
202
22,529
Roni Shouval retweeted
Tanya Bondar@_TanyaBondar_May 27
Intrigued that endogenous T-cells peak in the CNS hand-in-hand with CAR-T cells... does not prove causal T-cell autoreactivity in parkinsonism but begs the question about its potential contribution.
Blood Cancer Discovery@BCD_AACRMar 27
Now online: Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy doi.org/10.1158/2643-3230.BC…
8
20
2,593
A balanced discussion on the impact of #CART infusion timing in LBCL @BrianHill_MDPhD @AgrimaMianMD ashpublications.org/thehemat…

Is the Clock in the CAR Ticking? Conflicting Signals on Impact of Infusion Time of Day on Outcomes...

Luan D, Valid OB, Beyar-Katz O, . Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma. Blood. Published online December 23, 2025. PubM

ashpublications.org
9
2
37
4,931
New online! Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders dlvr.it/TS2wGd

Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy...

Nature Reviews Clinical Oncology - Rare lymphoproliferative and lymphomatous disorders occurring after chimeric antigen receptor (CAR) T cell therapy are garnering increased attention but remain...

nature.com
1
3
1
12
2,349
Roni Shouval retweeted
Oded Rechavi
@OdedRechaviApr 16
Announced by the ERC today (really bad news for science!!! It starts in Europe but will affect everybody) Because the REVIEWING LOAD is so bad, if your application fails you may need to wait mulitple years (>3?!?) until you can submit again! The ERC is the lifeline of the leading labs in Europe, so many research programs will be terminated (just no other sources to compensate). The letter from the ERC says “the only way is to reduce applications” (highlighted in the picture below) No!!! It's the wrong direction. Use AI to assist review. It’s not perfect (yet), but it allows more proposals to be evaluated, and it could support, not replace, human reviewers.
54
132
37
456
122,268
Roni Shouval retweeted
Ruella Lab@RuellaLabApr 16
📣Out today in @BloodPortfolio: harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies. 🔗 authors.elsevier.com/a/1my0Z… Congrats to @AlbertoCarturan & @Mat_Angelos! @MarcoRuella @PennMedicine @PennCancer @PennMedCSO
1
8
1
21
3,145
🔬 COSTEM 2026 | Berlin | Oct 1–4 The full scientific program is now available - explore key topics, sessions & expert discussions shaping the field. 📝 Submit your abstract bit.ly/3TpBCKk 🎯Register now bit.ly/4a1Pzn7 🎥Watch a highlight from COSTEM 2025
5
16
3,309
Roni Shouval retweeted
Yi Lin@YiLinMDPhDApr 11
Online @BloodAdvances @MayoCancerCare risk factors associated with IEC-enterocolitis after #CiltaCel #CART #mmsm & clinical course. Truly a multidisciplinary effort @NavreetChowlaMD Dr. Eric Chen Dr. Ken Lim @Rfonsi1 @Leif_Bergsagel @myelomaMD doi.org/10.1182/bloodadvance…
1
12
1
29
3,517
Roni Shouval retweeted
Neela Easton@EastonNeela33Mar 28
pubmed.ncbi.nlm.nih.gov/4188… Check out our meta-analysis on non-ICANS neurotoxicity after CAR T in myeloma patients, in which we shed light on a previously poorly characterized entity! 🧠 Great experience working with @KRejeski @RShouval @HBesien @samyamshon

Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of...

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapies have drastically improved outcomes for patients with relapsed or refractory multiple myeloma. Although...

pubmed.ncbi.nlm.nih.gov
2
12
673
Load more